Amryt licenses Lojuxta (lomitapide) from Aegerion Pharma across the European Union and other territories. Lojuxta is used to treat Homozygous Familial Hypercholesterolemia .

Amryt, a clinical-stage specialty pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that it has reached an agreement with Aegerion Pharmaceuticals, Inc.for the exclusive rights to sell Aegerion's drug, Lojuxta (lomitapide), across the European Union and other territories. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia ("HoFH") and was approved in the EU in late 2013.

Lojuxta currently generates material sales from the territories to be licensed by Amryt. Aegerion recorded $22.0 million in net product sales of lomitapide capsules in the third quarter of 2016, 15% of which was from prescriptions written outside of the US, including the territories now being licensed to Amryt. Amryt believes that there is significant potential for the drug to become a mainstay treatment for patients with HoFH.

Under the terms of the Licence Agreement, Amryt has the exclusive right to sell Lojuxta across the European Economic Area , Middle East and North Africa , Turkey and Israel. In return, Amryt will make royalty payments to Aegerion, paid quarterly, based on a percentage of sales, and once-off commercial milestone payments, subject to achieving certain sales targets. The Licence Agreement has an initial term until 1 January 2024 ("Initial Term"). On expiry of the Initial Term, Amryt may, at its discretion, extend the Licence Agreement for a further five years with the right to extend in further five year periods, subject to certain conditions. Amryt will also take on the ongoing regulatory and post-marketing obligations and commitments in support of Lojuxta.